Literature DB >> 8981754

Synthesis and microbiological evaluations of (N-heteroaryl) arylmethanamines and their Schiff bases.

R Fioravanti1, M Biava, S Donnarumma, G C Porretta, N Simonetti, A Villa, A Porta-Puglia, D Deidda, C Maulla, R Pompei.   

Abstract

The synthesis as well as the antimicrobial and antiviral activities of new (N-heteroaryl)arylmethanamines and their Schiff bases are reported. None of the tested compounds shown activity against Herpes simplex virus type 2 and against Gram positive and Gram negative bacteria. Weak or moderate activity on poliovirus Sabin type 1, on reverse transcriptase and against Cryptococcus neoformans was shown by some of the tested compounds. Viceversa several synthesized compounds exhibited a moderate or good activity against strains of Candida albicans, while only some of the tested compounds were found moderately active against strains of Candida sp. Instead numerous new compounds 3 or 4 were active as control against isolates of plant pathogenic fungi. The obtained results are discussed on the basis of structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981754

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  2 in total

1.  Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains.

Authors:  D Deidda; G Lampis; R Fioravanti; M Biava; G C Porretta; S Zanetti; R Pompei
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

2.  Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.

Authors:  Giovanna Poce; Robert H Bates; Salvatore Alfonso; Martina Cocozza; Giulio Cesare Porretta; Lluís Ballell; Joaquin Rullas; Fátima Ortega; Alessandro De Logu; Emanuela Agus; Valentina La Rosa; Maria Rosalia Pasca; Edda De Rossi; Baojie Wae; Scott G Franzblau; Fabrizio Manetti; Maurizio Botta; Mariangela Biava
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.